APTOCROM Inc. Stock

A109960

KR7109960005

Pharmaceuticals

End-of-day quote Korea S.E. 2026-11-12			5-day change	1st Jan Change
1,654.00 ^KRW	-0.06%		-3.50%	-66.92%

Sep. 22	Aprogen Medicines Inc. announced that it has received KRW 20 billion in funding from N2Tech Co.,Ltd, APTOCROM Inc., Aprogen Pharma Inc.	CI
Sep. 03	Aprogen Medicines Inc. announced that it expects to receive KRW 20 billion in funding from N2Tech Co.,Ltd, APTOCROM Inc., Aprogen Pharma Inc.	CI

Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-11-11	₩1,654.00	-0.06%	756
26-11-11	₩1,655.00	+0.85%	149
26-11-10	₩1,641.00	+0.06%	5,447
26-11-09	₩1,640.00	0.00%	725
26-11-06	₩1,640.00	-2.73%	5,081

End-of-day quote Korea S.E.

More quotes

Stock Market
Stocks
A109960 Stock

Market Cap	25.02B 18.74M 16.95M 15.65M 14.16M 26.72M 1.76B 27.53M 188M 74.63M 942M 70.35M 68.85M 3B	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	7.83B 5.87M 5.3M 4.9M 4.43M 8.36M 551M 8.61M 58.76M 23.35M 295M 22.01M 21.54M 938M	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	14.22%	Yield 2024 *	-	Yield 2025	-

Sep. 22	Aprogen Medicines Inc. announced that it has received KRW 20 billion in funding from N2Tech Co.,Ltd, APTOCROM Inc., Aprogen Pharma Inc.	CI
Sep. 03	Aprogen Medicines Inc. announced that it expects to receive KRW 20 billion in funding from N2Tech Co.,Ltd, APTOCROM Inc., Aprogen Pharma Inc.	CI
Aug. 13	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jun. 30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
May. 25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
May. 14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
May. 07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
Apr. 27	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
Apr. 27	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
Mar. 20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 15	APTOCROM Inc. announces Annual dividend	CI
Nov. 13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

1 day	-0.06%
1 week	-3.50%
Current month	-5.97%
1 month	-14.17%
3 months	-2.76%
6 months	-45.95%
Current year	-66.92%

1 week	1,382	1,709
1 month	1,382	1,939
Current year	1,382	5,400
1 year	1,382	6,100
3 years	1,382	18,800
5 years	1,382	76,300
10 years	1,382	395,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	2022-03-22
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-
Jong-Su Kang SAM	Sales & Marketing	62	-

APTOCROM Inc. Stock

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news: APTOCROM Inc.

Quotes and Performance

Price Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Director	Title	Age	Since
Soon-Kyu Park BRD	Director/Board Member	59	-
Jung-Chool Kim BRD	Director/Board Member	70	2022-03-22
Jae-Seob Kim BRD	Director/Board Member	63	2017-01-09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	-0.06%	-3.50%	-70.57%	-89.90%	18.71M
ELI LILLY AND COMPANY	-0.13%	+5.34%	+41.25%	+134.63%	1,280B
JOHNSON & JOHNSON	+1.49%	+4.68%	+46.64%	+93.09%	675B
ABBVIE INC.	+0.23%	+2.55%	+26.73%	+113.20%	521B
ROCHE HOLDING AG	+1.14%	+3.78%	+39.98%	+70.26%	386B
MERCK & CO., INC.	+0.21%	+0.55%	+61.56%	+44.18%	363B
NOVARTIS AG	+1.11%	+0.07%	+28.19%	+58.61%	301B
ASTRAZENECA PLC	+0.24%	-0.80%	+3.05%	+35.93%	286B
AMGEN INC.	-0.05%	+1.73%	+39.24%	+75.57%	253B
GILEAD SCIENCES, INC.	-0.34%	+0.96%	+37.10%	+125.78%	211B
Average	+0.39%	-0.38%	+25.32%	+66.14%	428B
Weighted average by Cap.	+0.42%	+0.20%	+38.14%	+96.09%

	2024	2025
Net sales	16.4B 12.29M 11.11M 10.26M 9.28M 17.52M 1.15B 18.04M 123M 48.92M 617M 46.11M 45.13M 1.97B	9.81B 7.35M 6.64M 6.13M 5.55M 10.47M 691M 10.79M 73.61M 29.25M 369M 27.57M 26.99M 1.18B
Net income	-28.09B -21.05M -19.03M -17.57M -15.9M -30.01M -1.98B -30.91M -211M -83.79M -1.06B -78.99M -77.3M -3.37B	-5.56B -4.16M -3.77M -3.48M -3.15M -5.94M -392M -6.12M -41.73M -16.58M -209M -15.63M -15.3M -666M
Net Debt	-25.07B -18.78M -16.98M -15.67M -14.19M -26.77M -1.77B -27.58M -188M -74.77M -944M -70.48M -68.97M -3B	-17.19B -12.88M -11.65M -10.75M -9.73M -18.36M -1.21B -18.91M -129M -51.28M -647M -48.34M -47.31M -2.06B